Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Pathophysiology of diabetic dyslipidaemia.

Filippatos T, Tsimihodimos V, Pappa E, Elisaf M.

Curr Vasc Pharmacol. 2017 Jan 31. doi: 10.2174/1570161115666170201105425. [Epub ahead of print]

PMID:
28155609
2.

Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis.

Barkas F, Elisaf M, Tsimihodimos V, Milionis H.

Diabetes Metab. 2017 Feb;43(1):1-8. doi: 10.1016/j.diabet.2016.10.006. Review.

PMID:
27916514
3.

Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.

Tsimihodimos V, Filippatos TD, Elisaf MS.

Expert Opin Drug Metab Toxicol. 2016 Nov 17:1-10. [Epub ahead of print]

PMID:
27819144
4.

Renoprotective effects of SGLT2 inhibitors: Beyond glucose reabsorption inhibition.

Tsimihodimos V, Filippatos TD, Fillippas-Ntekouan S, Elisaf MS.

Curr Vasc Pharmacol. 2016 Oct 7. [Epub ahead of print]

PMID:
27748201
5.

Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors.

Filippatos TD, Tsimihodimos V, Elisaf MS.

Expert Opin Pharmacother. 2016 Aug;17(12):1581-3. doi: 10.1080/14656566.2016.1201073. No abstract available.

PMID:
27295549
6.

Effects of benchmarking on the quality of type 2 diabetes care: results of the OPTIMISE (Optimal Type 2 Diabetes Management Including Benchmarking and Standard Treatment) study in Greece.

Tsimihodimos V, Kostapanos MS, Moulis A, Nikas N, Elisaf MS.

Ther Adv Endocrinol Metab. 2015 Oct;6(5):199-209. doi: 10.1177/2042018815592803.

7.

Hypercalcemia and acute renal failure associated with calcium carbonate consumption in a patient with hypoparathyroidism.

Mitrogianni Z, Tsimihodimos V, Tzavella E, Elisaf M.

Arch Med Sci. 2014 Dec 22;10(6):1255-7. doi: 10.5114/aoms.2014.47835. No abstract available.

8.

Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece.

Kostapanos MS, Tsimihodimos V, Elisaf MS, Tzouvelekis E, Nikas N.

World J Diabetes. 2014 Feb 15;5(1):76-83. doi: 10.4239/wjd.v5.i1.76.

9.

Summarizing the FIELD study: lessons from a 'negative' trial.

Tsimihodimos V, Mikhailidis DP, Elisaf M.

Expert Opin Pharmacother. 2013 Dec;14(18):2601-10. doi: 10.1517/14656566.2013.850075. Review.

PMID:
24206060
10.

Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes.

Filippatos TD, Rizos EC, Tsimihodimos V, Gazi IF, Tselepis AD, Elisaf MS.

Lipids. 2013 Jun;48(6):547-55. doi: 10.1007/s11745-013-3787-1.

PMID:
23546765
11.

Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study.

Filippatos TD, Derdemezis CS, Voulgari PV, Tsimihodimos V, Elisaf MS, Tselepis AD, Drosos AA.

Scand J Rheumatol. 2013;42(3):169-75. doi: 10.3109/03009742.2012.745013.

PMID:
23311768
12.

How should we treat hypertension and dyslipidemia in patients with prediabetes?

Tsimihodimos V, Florentin M, Elisaf MS.

Curr Pharm Des. 2013;19(21):3773-87. Review.

PMID:
23286438
13.

Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives.

Moutzouri E, Tsimihodimos V, Tselepis AD.

Curr Pharm Des. 2013;19(21):3827-40. Review.

PMID:
23286437
14.

Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.

Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS.

Int J Clin Pract. 2012 Sep;66(9):843-53. doi: 10.1111/j.1742-1241.2012.02972.x.

PMID:
22897461
15.

Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review.

Rizos EC, Ntzani EE, Papanas N, Tsimihodimos V, Mitrogianni Z, Maltezos E, Elisaf MS.

Curr Vasc Pharmacol. 2013 Nov;11(6):992-1000. Review.

PMID:
22724475
16.

A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.

Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS.

Metabolism. 2012 Jul;61(7):906-21. doi: 10.1016/j.metabol.2011.12.002. Review.

PMID:
22304839
17.

Prediabetes: to treat or not to treat?

Moutzouri E, Tsimihodimos V, Rizos E, Elisaf M.

Eur J Pharmacol. 2011 Dec 15;672(1-3):9-19. doi: 10.1016/j.ejphar.2011.10.007. Review.

PMID:
22020287
18.

Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile.

Filippatos TD, Tsimihodimos V, Derdemezis CS, Gazi IF, Saougos V, Mikhailidis DP, Tselepis AD, Elisaf MS.

Nutr Metab Cardiovasc Dis. 2013 Apr;23(4):330-6. doi: 10.1016/j.numecd.2011.07.002.

PMID:
21963513
19.

Effect of Plant Polyphenols on Adipokine Secretion from Human SGBS Adipocytes.

Derdemezis CS, Kiortsis DN, Tsimihodimos V, Petraki MP, Vezyraki P, Elisaf MS, Tselepis AD.

Biochem Res Int. 2011;2011:285618. doi: 10.1155/2011/285618.

20.

The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.

Agouridis AP, Tsimihodimos V, Filippatos TD, Dimitriou AA, Tellis CC, Elisaf MS, Mikhailidis DP, Tselepis AD.

Expert Opin Pharmacother. 2011 Dec;12(17):2605-11. doi: 10.1517/14656566.2011.591383.

PMID:
21714585
Items per page

Supplemental Content

Loading ...
Support Center